The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Li Dean Y since 2021.
This trader's CIK number is 1837016.
At the time of last reporting, Li Dean Y was the Executive VP & President, MRL of Merck & Co., Inc.. (stock ticker symbol MRK).
Also see all insider trading activities at Merck & Co., Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | RXRX | 0 | $0 | 29,000 | $401,331 | 0 | $0 |
2021 | RXRX | 0 | $0 | 35,000 | $714,886 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | MRK | 0 | $0 | 14,702 | $1,845,086 | 14,702 | $912,553 |
2023 | MRK | 0 | $0 | 0 | $0 | 1,062 | $122,629 |
2022 | MRK | 0 | $0 | 0 | $0 | 1,834 | $161,853 |
2021 | MRK | 0 | $0 | 0 | $0 | 2,474 | $185,340 |
1. Recursion Pharmaceuticals, Inc. (RXRX)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-01-09 | RXRX | Sale | 29,000 | 13.84 | 401,331 |
2021-12-07 | RXRX | Sale | 15,900 | 20.75 | 329,925 |
2021-11-17 | RXRX | Sale | 5,626 | 20.04 | 112,733 |
2021-11-19 | RXRX | Sale | 13,474 | 20.20 | 272,228 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-02-09 | MRK | Option Ex | 14,702 | 62.07 | 912,553 |
2024-02-09 | MRK | Sale | 14,702 | 125.50 | 1,845,086 |
2023-05-01 | MRK | Option Ex | 1,062 | 115.47 | 122,629 |
2022-05-03 | MRK | Option Ex | 773 | 87.65 | 67,753 |
2022-05-01 | MRK | Option Ex | 1,061 | 88.69 | 94,100 |
2021-05-04 | MRK | Option Ex | 694 | 75.98 | 52,730 |
2021-05-01 | MRK | Option Ex | 1,030 | 74.50 | 76,735 |
2021-05-03 | MRK | Option Ex | 750 | 74.50 | 55,875 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Li Dean Y (Executive VP & President, MRL of Merck & Co., Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.